'Fev 1' diaporamas de présentation

Riacutizzazione di BPCO

Riacutizzazione di BPCO. Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper. Riacutizzazioni: definizione

1.06k views • 84 slides

Asthma

Asthma. Michelle Harkins, MD University of New Mexico Pulmonary and Critical Care Project Echo. Asthma and School Absences. Asthma is one of the leading causes of school absenteeism.

963 views • 65 slides

Terapia della fase stabile della BPCO: farmacoterapia

891 views • 62 slides

Chronic Obstructive Pulmonary Disease (COPD)

Chronic Obstructive Pulmonary Disease (COPD). Omer Alamoudi, MD, FRCP,FCCP,FACP Professor, consultant Pulmonologist dramoudi@yahoo.com. Definition of COPD. COPD is a chronic obstructive pulmonary disease that is characterized by airflow limitation that is not fully reversible.

1.23k views • 62 slides

Dept.Pulmonology, University of Szeged, Deszk, Hungary

Prof. Attila Somfay. Dept.Pulmonology, University of Szeged, Deszk, Hungary. COPD. 58-year-old male smoker. Progradiating effort dyspnoe for 4 years Medical history: hypertension, recidiv stroke Dg: CHF,hypertonia, hypertrigliceridaemia

836 views • 55 slides

Szefler SJ, J Allergy Clin Immunol 2007;120:1043

p= 0.03. What would be the prophylactic treatment in children with mild persistent asthma younger than 8 years old? Budesonide / Montelukast. Szefler SJ, J Allergy Clin Immunol 2007;120:1043. Budesonide= 500 m g/day, nebules n= 134 Montelukast= 4-5 mg /day,tbt. n= 146.

681 views • 53 slides

Dipartimento di Medicina e Chirurgia Generale

AUSL 8 AREZZO. BPCO: una malattia sistemica ? Emilio Santoro Medicina Interna - Ospedale del Casentino. Dipartimento di Medicina e Chirurgia Generale. Alveolar wall destruction EMPHYSEMA. Proteases. Mucus hypersecretion CHRONIC BRONCHITIS. Pathogenesis of COPD.

777 views • 52 slides

CPET in Differential Diagnosis

CPET in Differential Diagnosis. Gaye ULUBAY, MD, Assoc. Prof. Baskent University Faculty of Medicine Department of Pulmonary Diseases Ankara, Turkey. Pulmonary circulation. Peripheral circulation. VCO 2. CO2 PROD. EXPIRED. O2 FLOW. Creat ?PO 4. Muscle. Lungs. Heart and blood.

804 views • 46 slides

Asthma in childhood

Asthma in childhood. E. Picard M.D. Pediatric Pulmonary Unit Shaare Zedek Medical Center Jerusalem. ASTHMA: DEFINITION. Asthma is a chronic inflammatory disease of the airways characterized by reversible obstruction of airflow. Asthma: inflammation. Normal. Asthma.

1.11k views • 42 slides

Spirometry, assessment of bronchial responsiveness and induced sputum

675 views • 42 slides

LA CRISI ASMATICA

601 views • 40 slides

??? ??? ??

??? ??? ??. ????? ???? ??? 2013.6.11. Asthma Pulmonary embolism Infection (CAP, TBc). Asthma. F/29 CC: Dyspnea, wheezing(+). Special consideration - Pregnancy. Severity : 1/3 ? ?? , 1/3 ? ?? , 1/3 ? unchanged Tx : theophylline, ICS, BA, leukotriene modifier(montelukast)

808 views • 37 slides

ADVAIR TM DISKUS (R) (Fluticasone propionate/salmeterol inhalation powder)

ADVAIR TM DISKUS (R) (Fluticasone propionate/salmeterol inhalation powder). Pulmonary and Allergy Drugs Advisory Committee Meeting Gaithersburg, Maryland January 17, 2002 Lydia I. Gilbert-McClain, MD, FCCP Medical Reviewer, DPADP. CLINICAL ISSUES. Clinical relevance of the Efficacy data

747 views • 34 slides

Prof. Dr. U. Wahn

494 views • 33 slides

Indications for Antibiotics in Exacerbations of COPD

Indications for Antibiotics in Exacerbations of COPD. Sanjay Sethi MD Professor Pulmonary, Critical Care and Sleep Medicine University at Buffalo, SUNY ssethi@buffalo.edu. Myths in AECOPD. Exacerbations are harmless Exacerbations resolve spontaneously

559 views • 33 slides

Asthme Aigu Grave Prise en charge initiale

893 views • 30 slides

Pulmonary Function Measurements

Pulmonary Function Measurements. CHAPTER 5 DR. CARLOS ORTIZ BIO-208. PULMONARY FUNCTION.

341 views • 14 slides

PRESENTAZIONE E DISCUSSIONE DEGLI ELABORATI DEI GRUPPI DI LAVORO

213 views • 9 slides

Placebo Enrolled Group vs All UPMC Unenrolled Who Survived > 30 Days Posttransplant

Chiron Briefing Document Figure 4.3.1.2-1. Placebo Enrolled Group vs All UPMC Unenrolled Who Survived > 30 Days Posttransplant. 100. 90. 80. 70. 60. P = .9908. Survival (%). 50. 40. 30. Placebo (n = 30) Screen failures > 30 days (n = 45). 20. 10. 0. 0. 6. 12. 18. 24. 30. 36.

194 views • 9 slides

Objective

Objective To investigate whether particulate air pollutants exposure may affect long-term changes of childhood atopic disease and respiratory inflammation?

98 views • 1 slides